Assessment of EGFR Genomic Alterations as Prognostic Markers in Cervical Cancer
This study is done to gather preliminary data for determining the best way to test EGFR
expression in patients with cervical cancer who will receive treatment with EGFR inhibitors
in the future.
This study is designed to obtain preliminary data of genomic and phenotypic alterations of
the EGFR pathway in high grade cervical intraepithelial lesions (HG-SIL) and invasive
cervical cancers (CC) to be used later for therapeutic guidance and to evaluate genomic
(over-expression, amplification, point mutations, etc.) and phenotypic alterations of other
transduction pathways interacting with the EGFR pathway.
Claire Verschraegen, MD
University of New Mexico
United States: Institutional Review Board
|University of New Mexico||Albuquerque, New Mexico 87131|